<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NAPHAZOLINE HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(naf-az'oh-leen)<br/><span class="topboxtradename">Ak-Con, </span><span class="topboxtradename">Albalon, </span><span class="topboxtradename">Allerest, </span><span class="topboxtradename">Clear Eyes, </span><span class="topboxtradename">Comfort, </span><span class="topboxtradename">Degest-2, </span><span class="topboxtradename">Muro's Opcon, </span><span class="topboxtradename">Nafazair, </span><span class="topboxtradename">Naphcon, </span><span class="topboxtradename">Privine, </span><span class="topboxtradename">VasoClear, </span><span class="topboxtradename">Vasocon<br/></span><b>Classifications:</b> <span class="classification">eye, ear, nose and throat (eent) preparation</span>; <span class="classification">vasoconstrictor</span>; <span class="classification">decongestant</span>; <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha-adrenergic agonist (sympathomimetic)</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.012%, 0.02%, 0.03%, 0.1% ophthalmic solution; 0.05% nasal solution</p>
<h1><a name="action">Actions</a></h1>
<p>Direct-acting imidazoline derivative with marked alpha-adrenergic activity. Differs from other sympathomimetic amines in that
         systemic absorption may cause CNS depression rather than stimulation.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Produces rapid and prolonged vasoconstriction of arterioles, thereby decreasing fluid exudation and mucosal engorgement.</p>
<h1><a name="uses">Uses</a></h1>
<p>Nasal decongestant and ocular vasoconstrictor.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Narrow-angle glaucoma; concomitant use with MAO inhibitors or tricyclic antidepressants. Safety during pregnancy (category
         C), lactation, or in infants is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertension, cardiac irregularities, advanced arteriosclerosis; diabetes; hyperthyroidism; older adult patients.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Congestion</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Intranasal</span> 2 drops or sprays of 0.05% solution in each nostril q36h for no more than 35 d. <span class="rdroute">Ophthalmic</span> See Appendix A<br/><span class="rdage">Child:</span> <span class="rdroute">Intranasal</span> 12 drops or sprays of 0.025% solution q36h for no more than 35 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Instillation</span><br/><ul>
<li>Instill nasal spray with patient in upright position. If administered in reclining position, a stream rather than a spray
            may be ejected, with possibility of systemic reaction.
         </li>
<li>Minimize amount of drug swallowed by taking care not to direct the flow toward nasopharynx and by positioning patient properly
            with the head tilted slightly downward.
         </li>
<li>Store at 15°30° C (59°86° F), protect from freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity reactions, headache, nausea, weakness, sweating, drowsiness, hypothermia, <span class="speceff-life">coma</span>. <span class="typehead">CV:</span> Hypertension, bradycardia, <span class="speceff-life">shock-like hypotension</span>. <span class="typehead">Special Senses:</span> Transient nasal stinging or burning, dryness of nasal mucosa, pupillary dilation, increased intraocular pressure, rebound
      redness of the eye. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">tricyclic antidepressants</span>, <b>maprotiline</b> may potentiate pressor effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> Within 10 min. <span class="typehead">Duration:</span> 26 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Watch for rebound congestion and chemical rhinitis with frequent and continued use.</li>
<li>Monitor BP periodically for development or worsening of hypertension, especially with ophthalmic route.</li>
<li>Overdose: Bradycardia and hypotension can result. Report promptly.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not exceed prescribed regimen. Systemic effects can result from swallowing excessive medication.</li>
<li>Discontinue medication and contact physician if nasal congestion is not relieved after 5 d.</li>
<li>Prevent contamination of eye solution by taking care not to touch eyelid or surrounding area with dropper tip.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>